Eficácia e segurança das intervenções para hemangioma infantil em comparação com propranolol oral: revisão sistemática atualizada e metanálise da rede bayesiana
OncologiaResumo original em inglês
O que aconteceu
• Oral propranolol is the established first-line systemic therapy for infantile hemangioma. • Previous network meta-analyses have reported treatment rankings, but the clinical meaning of these rankings relative to oral propranolol remains uncertain.
O que encontraram
• Despite favorable point estimates for combination therapy and nadolol, this benchmark-anchored analysis found no included active intervention statistically superior to oral propranolol. • Certainty assessment showed that treatment rankings were limited by heterogeneity, inconsistency, risk of bias, and imprecision; atenolol had the largest body of direct comparative evidence among the alternatives.
Por que isso importa
By anchoring all comparisons to oral propranolol and integrating CINeMA certainty assessments with inconsistency testing, these findings are consistent with the continued role of oral propranolol as the reference systemic treatment for infantile hemangioma. For patients intolerant to propranolol, atenolol may represent a reasonable alternative.
Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.
O estudo original
Efficacy and safety of interventions for infantile hemangioma compared with oral propranolol: an updated systematic review and bayesian network meta-analysis
Caihong Li, Liehao Yang, Lingfeng Pan
Descritores MeSH
- Skin Neoplasms
- Hemangioma
- Propranolol
- Humans
- Infant
- Randomized Controlled Trials as Topic
- Administration, Oral
- Treatment Outcome
- Atenolol
- Bayes Theorem